A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer

2014111 citationsJournal Article

Authors

LY2510924 demonstrated CD34(+) cell mobilization at doses ≥2.5 mg/day with a tolerable safety profile up to an MTD of 20 mg/day.

Good health and well-being

Published in: Clinical Cancer Research

Volume 20, Issue 13, pp. 3581-3588

Field-Weighted Citation Impact: 5.82